Cited by 314Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorMental Health and Psychiatry

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol

Keefe, Richard S.E., Seidman, Larry J., Christensen, Bruce K., Hamer, Robert M., Sharma, Tonmoy, Sitskoorn, Margriet M., Lewine, Richard R.J., Yurgelun-Todd, Deborah A., Gur, Ruben C., Tohen, Mauricio, Tollefson, Gary D., Sanger, Todd M., Lieberman, Jeffrey A., HGDH Research Group·2004·American Journal of Psychiatry

DOI 10.1176/appi.ajp.161.6.985

Open this paper in CoChat — free account

Abstract

OBJECTIVE: The effect of antipsychotic medication on neurocognitive function remains controversial, especially since most previous work has compared the effects of novel antipsychotic medications with those of high doses of conventional medications. This study compares the neurocognitive effects of olanzapine and low doses of haloperidol in patients with first-episode psychosis. METHOD: Patients with a first episode of schizophrenia, schizoaffective disorder, or schizophreniform disorder (N=167) were randomly assigned to double-blind treatment with olanzapine (mean modal dose= 9.63 mg/day) or haloperidol (mean modal dose=4.60 mg/day) for the 12-week acute phase of a 2-year study. The patients were assessed with a battery of neurocognitive tests at baseline and 12 weeks after beginning treatment. RESULTS: An unweighted neurocognitive composite score, composed of measures of verbal fluency, motor functions, working memory, verbal memory, and vigilance, improved significantly with both haloperidol and olanzapine treatment (effect sizes of 0.20 and 0.36, respectively, no significant difference between groups). A weighted composite score developed from a principal-component analysis of the same measures improved to a significantly greater degree with olanzapine, compared with haloperidol. Anticholinergic use, extrapyramidal symptoms, and estimated IQ had little effect on the statistical differentiation of the medications, although duration of illness had a modest effect. The correlations of cognitive improvement with changes in clinical characteristics and with side effects of treatment were significant for patients who received haloperidol but not for patients who received olanzapine. CONCLUSIONS: Olanzapine has a beneficial effect on neurocognitive function in patients with a first episode of psychosis. However, in a comparison of the effects of olanzapine and low doses of haloperidol, the difference in benefit is small.

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.161.6.985

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The assessment and analysis of handedness: The Edinburgh inventory
Oldfield, R. C. (1971) · Neuropsychologia · doi:10.1016/0028-3932(71)90067-4 · Cited by 35,900
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A compendium of neuropsychological tests: administration, norms, and commentary
(1991) · Choice Reviews Online · doi:10.5860/choice.29-2400 · Cited by 6,118
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ‘‘right stuff’’?
Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033430 · Cited by 2,999
Wisconsin Card Sorting Test Manual – Revised and Expanded
Heaton, R. K., Chelune, C., Talley, J., Kay, G., & Curtiss, G. (1981) · Medical Entomology and Zoology · Cited by 2,975
Neurocognitive deficit in schizophrenia: A quantitative review of the evidence.
Heinrichs, R. W., & Zakzanis, K. K. (1998) · Neuropsychology · doi:10.1037/0894-4105.12.3.426 · Cited by 2,798
Wechsler Memory Scale-Revised
Peter, H., Penzel, T., Peter, J. H., & Peter, J. G. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_302294 · Cited by 2,278

Show all 47 references

Sorted by citations

Items 101–200 of 314

Increased Prolactin Levels Are Associated with Impaired Processing Speed in Subjects with Early Psychosis
Montalvo, I., Gutiérrez‐Zotes, A., Creus, M., Monseny, R., Ortega, L., Franch, J., Lawrie, S. M., Reynolds, R. M., Vilella, E., & Labad, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089428 · Cited by 54
Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia
Heresco‐Levy, U. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.4.827 · Cited by 53
Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders
Trampush, J. W., Lencz, T., DeRosse, P., John, M., Gallego, J. A., Petrides, G., Hassoun, Y., Zhang, J., Addington, J., Kellner, C. H., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv120 · Cited by 53
Self-citation
Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms
Riedel, M. J., Spellmann, I., Strassnig, M., Douhet, A., Dehning, S., Opgen-Rhein, M., Valdevit, R., Engel, R. R., Kleindienst, N., Müller, N., et al. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0739-x · Cited by 53
Neuroanatomical correlates of executive dysfunction in the at-risk mental state for psychosis
Koutsouleris, N., Patschurek‐Kliche, K., Scheuerecker, J., Decker, P., Ronald Bottlender, A., Schmitt, G., Rujescu, D., Giegling, I., Christian Gaser, B., Reiser, M. F., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.08.026 · Cited by 52
Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: A LORETA analysis of P300
Higuchi, Y., Sumiyoshi, T., Kawasaki, Y., Matsui, M., Arai, H., & Kurachi, M. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.020 · Cited by 52
The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements
Harvey, P. D., Green, M. F., Bowie, C. R., & Loebel, A. D. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0432-1 · Cited by 54
Haloperidol Dose When Used as Active Comparator in Randomized Controlled Trials With Atypical Antipsychotics in Schizophrenia
Hugenholtz, G. W. K., Heerdink, E. R., Stolker, J. J., Meijer, W. E. E., Egberts, T. C. G., & Nolen, W. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0606 · Cited by 51
Neurocognitive profile analysis in obsessive-compulsive disorder
BURDICK, K. E., ROBINSON, D. G., MALHOTRA, A. K., & SZESZKO, P. R. (2008) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617708080727 · Cited by 50
Delay discounting and task performance consistency in patients with schizophrenia
Weller, R. E., Avsar, K. B., Cox, J. E., Reid, M. A., White, D. M., & Lahti, A. C. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.11.013 · Cited by 54
Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia
Riedel, M. J., Müller, N., Spellmann, I., Engel, R. R., Musil, R., Valdevit, R., Dehning, S., Douhet, A., Cerovecki, A., Strassnig, M., et al. (2007) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0748-9 · Cited by 50
Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target
Barak, S., & Weiner, I. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.011 · Cited by 51
The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis
Faber, G., Smid, H. G. O. M., Gool, A. R. V., Wiersma, D., & van den Bosch, R. J. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.02.003 · Cited by 50
Assessment of subjective cognitive and emotional effects of antipsychotic drugs. Effect by defect?
Moritz, S., Andreou, C., Klingberg, S., Thoering, T., & Peters, M. J. V. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.039 · Cited by 49
1-year follow-up study of cognitive function in first-episode non-affective psychosis
Rodríguez-Sánchez, J. M., Pérez‐Iglesias, R., González‐Blanch, C., Pelayo‐Terán, J. M., Mata, I. F., Martínez, O., Cubillo, I. S., Vázquez‐Barquero, J. L., & Crespo‐Facorro, B. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.05.020 · Cited by 48
Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?
Bola, J. R. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj019 · Cited by 47
Less Unique Variance Than Meets the Eye: Overlap Among Traditional Neuropsychological Dimensions in Schizophrenia
Dickinson, D., & Gold, J. M. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm092 · Cited by 49
Executive function in schizophrenia: what impact do antipsychotics have?
O’Gráda, C., & Dinan, T. G. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.861 · Cited by 45
Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB)
McCleery, A., Green, M. F., Hellemann, G., Baade, L. E., Gold, J. M., Keefe, R. S. E., Kern, R. S., Mesholam-Gately, R. I., Seidman, L. J., Subotnik, K. L., et al. (2015) · Psychological Medicine · doi:10.1017/s0033291715000641 · Cited by 48
Self-citation
Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT 2A receptor agonism
Aringhieri, S., Kolachalam, S., Gerace, C., Carli, M., Verdesca, V., Brunacci, M. G., Rossi, C., Ippolito, C., Solini, A., Corsini, G. U., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.02.005 · Cited by 46
Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC
Baviera, M., Invernizzi, R. W., & Carli, M. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0959-9 · Cited by 43
A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning
Nuechterlein, K. H., Ventura, J., Subotnik, K. L., Gretchen‐Doorly, D., Turner, L. R., Casaus, L. R., Luo, J. S., Boucher, M. L., Hayata, J. N., Bell, M. D., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720003335 · Cited by 44
Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task
Bubeníková‐Valešová, V., Stuchlı́k, A., Svoboda, J., Bureš, J., & Valeš, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711273105 · Cited by 43
A Review of Second-Generation Antipsychotic Discontinuation in First-Episode Psychosis
Miller, B. J. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000336756.65308.83 · Cited by 42
Management of Patients Presenting with Acute Psychotic Episodes of Schizophrenia
Thomas, P., Alptekın, K., Gheorghe, M., Mauri, M., Olivares, J. M., & Riedel, M. J. (2009) · CNS Drugs · doi:10.2165/00023210-200923030-00002 · Cited by 45
First- and second-generation antipsychotic medication and cognitive processing in schizophrenia
Weickert, T. W., & Goldberg, T. E. (2005) · Current Psychiatry Reports · doi:10.1007/s11920-005-0085-5 · Cited by 41
Recovery, not progressive deterioration, should be the expectation in schizophrenia
Zipursky, R. B., & Agid, O. (2015) · World Psychiatry · doi:10.1002/wps.20194 · Cited by 40
A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia
Sarter, M. F., Martínez, V., & Kozak, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1216-6 · Cited by 42
Antipsychotic medication for early episode schizophrenia
Bola, J. R., Kao, D., Soydan, H., & Adams, C. E. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006374.pub2 · Cited by 43
Clozapine Treatment Causes Oxidation of Proteins Involved in Energy Metabolism in Lymphoblastoid Cells: A Possible Mechanism for Antipsychotic- Induced Metabolic Alterations
Baig, M. R., Navaira, E., Escamilla, M., Raventós, H., & Walss‐Bass, C. (2010) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000388627.36781.6a · Cited by 41
Metaphor comprehension deficit in schizophrenia with reference to the hypothesis of abnormal lateralization and right hemisphere dysfunction
Chakrabarty, M., Sarkar, S., Chatterjee, A., Ghosal, M. K., Guha, P., & Deogaonkar, M. S. (2014) · Language Sciences · doi:10.1016/j.langsci.2014.01.002 · Cited by 39
Dissociation of long-term verbal memory and fronto-executive impairment in first-episode psychosis
Leeson, V. C., Robbins, T. W., Franklin, C., Harrison, M., Harrison, I., Ron, M. A., Barnes, T. R. E., & Joyce, E. M. (2009) · Psychological Medicine · doi:10.1017/s0033291709005935 · Cited by 39
Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates
Dorofeikova, M., Незнанов, Н. Г., & Петрова, Н. Н. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.09.041 · Cited by 37
Analyzing the influence of BDNF heterozygosity on spatial memory response to 17β-estradiol
Wu, Y., Du, X., van den Buuse, M., & Hill, R. (2015) · Translational Psychiatry · doi:10.1038/tp.2014.143 · Cited by 39
Disparate effects of first and second generation antipsychotics on cognition in schizophrenia – Findings from the randomized NeSSy trial
Veselinović, T., Scharpenberg, M., Heinze, M., Cordes, J., Mühlbauer, B., Juckel, G., Habel, U., Rüther, E., Timm, J., Gründer, G., et al. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.03.014 · Cited by 39
Role of the NRG1/ErbB4 and PI3K/AKT/mTOR Signaling Pathways in the Antipsychotic Effects of Aripiprazole and Sertindole in Ketamine-Induced Schizophrenia-Like Behaviors in Rats
Nawwar, D. A., Zaki, H. F., & Sayed, R. H. (2021) · Inflammopharmacology · doi:10.1007/s10787-022-01031-w · Cited by 40
Open, randomized trial of the effects of aripiprazole versus risperidone on social cognition in schizophrenia
Maat, A., Cahn, W., Gijsman, H. J., Hovens, J. E. J. M., Kahn, R. S., & Aleman, A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.009 · Cited by 35
Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: A naturalistic 12-month follow-up study
Guo, X., Zhai, J., Wei, Q., Twamley, E. W., Jin, H., Fang, M., Hu, M., & Zhao, J. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.08.027 · Cited by 35
La mémoire de travail dans la schizophrénie : revue de la littérature
Kébir, O., & Tabbane, K. (2008) · L Encéphale · doi:10.1016/j.encep.2006.12.008 · Cited by 39
Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics
Spellmann, I., Müller, N., Musil, R., Zill, P., Douhet, A., Dehning, S., Cerovecki, A., Bondy, B., Möller, H., & Riedel, M. J. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-0800-9 · Cited by 34
Correlation between duration of untreated psychosis and long-term prognosis in chronic schizophrenia
Yu, M., Tan, Q., Wang, Y., Xu, Y., Wang, T., Liu, D., Chen, D., Deng, P., Huang, C., Liang, X., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1112657 · Cited by 32
Early intervention in schizophrenia: Current and future perspectives
Keshavan, M. S., & Amirsadri, A. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0040-8 · Cited by 32
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone
Ayesa‐Arriola, R., Rodríguez-Sánchez, J. M., Pérez‐Iglesias, R., Roiz‐Santiáñez, R., Martínez‐García, O., Sánchez‐Moreno, J., Tabarés‐Seisdedos, R., Vázquez‐Barquero, J. L., & Crespo‐Facorro, B. (2013) · Psychopharmacology · doi:10.1007/s00213-013-2994-z · Cited by 31
Cognitive performance during the first year of treatment in first-episode schizophrenia: a case–control study
Olivier, M. R., Killian, S., Chiliza, B., Asmal, L., Schoeman, R., Oosthuizen, P., Kidd, M., & Emsley, R. A. (2015) · Psychological Medicine · doi:10.1017/s0033291715000860 · Cited by 31
The α2C-adrenoceptor antagonist, ORM-10921, has antipsychotic-like effects in social isolation reared rats and bolsters the response to haloperidol
Uys, M. M., Shahid, M., Sallinen, J., Dreyer, W., Cockeran, M., & Harvey, B. H. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.07.002 · Cited by 32
Pharmacological Approaches to the Management of Cognitive Dysfunction in Schizophrenia
Harvey, P. D., & McClure, M. M. (2006) · Drugs · doi:10.2165/00003495-200666110-00004 · Cited by 31
Standardizing the use of the Continuous Performance Test in schizophrenia research: A validation study
Kahn, P. V., Walker, T. M., Williams, T. S., Cornblatt, B. A., Mohs, R. C., & Keefe, R. S. E. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.09.009 · Cited by 31
Self-citation
Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients
Lee, S.-M., Chou, Y.-H., Li, M., Wan, F.-J., & Yen, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.03.016 · Cited by 30
Olanzapine interactions with nicotine and mecamylamine in rats: Effects on memory function
Levin, E. D., Petro, A. E., & Beatty, A. (2005) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2005.01.011 · Cited by 30
Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment
Amitai, N., & Markou, A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.08.025 · Cited by 33
Neurocognitive individualized training versus social skills individualized training: A randomized trial in patients with schizophrenia
Bucci, P., Piegari, G., Mucci, A., Merlotti, E., Chieffi, M., Riso, F. D., Angelis, M. D., Munzio, W. D., & Galderisi, S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.053 · Cited by 28
Comparing the effect of the subcategories of atypical antipsychotic medications on cognition in schizophrenia using a meta-analytic approach
Clissold, M., & Crowe, S. F. (2018) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2018.1488952 · Cited by 26
Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial
Albert, N., Randers, L., Allott, K., Jensen, H., Melau, M., Hjorthøj, C. R., & Nordentoft, M. (2018) · Psychological Medicine · doi:10.1017/s0033291718001836 · Cited by 28
The Italian guidelines for early intervention in schizophrenia: development and conclusions
MASI, S. D., Sampaolo, L., Mele, A., Morciano, C., Cappello, S., Meneghelli, A., & de Girolamo, G. (2008) · Early Intervention in Psychiatry · doi:10.1111/j.1751-7893.2008.00091.x · Cited by 27
Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot
Möller, H. ‐. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.03.006 · Cited by 27
Early intervention in psychotic disorders: Challenges and relevance in the Indian context
Keshavan, M., Shrivastava, A., & Gangadhar, B. N. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.69228 · Cited by 27
A neuropsychological study of patients with temporal lobe epilepsy and chronic interictal psychosis
Flügel, D., O’Toole, A., Thompson, P. J., Koepp, M. J., Cercignani, M., Symms, M. R., & Foong, J. (2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.05.018 · Cited by 26
Electrical brain activity and response to olanzapine in schizophrenia: A study with LORETA images of P300
Sumiyoshi, T., Higuchi, Y., Kawasaki, Y., Matsui, M., Kato, K., Yuuki, H., Arai, H., & Kurachi, M. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.04.028 · Cited by 25
Antipsychotic effects on cognition in schizophrenia: A meta-analysis of randomised controlled trials
Guilera, G., Pino, Ó., Gómez‐Benito, J., & Rojo, E. (2009) · The European Journal of Psychiatry · doi:10.4321/s0213-61632009000200002 · Cited by 25
Clinical effectiveness in first-episode patients
Ohlsen, R. I., O’Toole, M., Purvis, R. G., Walters, J., Taylor, T. M., JONES, H. M., & Pilowsky, L. S. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.08.003 · Cited by 25
Implementation considerations for multisite clinical trials with cognitive neuroscience tasks
Keefe, R. S. E., & Harvey, P. D. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn042 · Cited by 24
Self-citation
Cognitive deficits, clinical variables, and white matter microstructure in schizophrenia: a multisite harmonization study
Seitz‐Holland, J., Wojcik, J., Karayumak, S. C., Lyall, A. E., Pasternak, O., Yogesh Rathi, A., Vangel, M. G., Pearlson, G. D., Tamminga, C. A., Sweeney, J. A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01731-3 · Cited by 25
Cognitive function, social functioning and quality of life in first-episode psychosis: A 1-year longitudinal study
Popolo, R., Vinci, G., & Balbi, A. (2010) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651500903282881 · Cited by 26
Cognitive Remediation for the Treatment of Cognitive Dysfunction in the Early Course of Psychosis
Lewandowski, K. E. (2016) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000108 · Cited by 23
Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo
Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., & Möller, H. (2006) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832006000700003 · Cited by 24
Self-citation
Social Cognition and Visual Perception in Schizophrenia Inpatients Treated with First-and Second-Generation Antipsychotic Drugs
Kucharska‐Pietura, K., Mortimer, A. M., Tylec, A., & Czernikiewicz, A. (2012) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.6.1.2 · Cited by 24
Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia
van Veelen, N. M. J., Grootens, K. P., Peuskens, J., Sabbe, B., Salden, M. E., Verkes, R. J., Kahn, R. S., & Sitskoorn, M. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.011 · Cited by 21
Self-citation
Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia
Macfadden, W., Bossie, C. A., Turkoz, I., & Haskins, J. T. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283347cbf · Cited by 21
Sertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPP
Carli, M., Calcagno, E., Mainini, E., Arnt, J., & Invernizzi, R. W. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2066-6 · Cited by 20
Region Specific Regulation of NR1 in Rhesus Monkeys Following Chronic Antipsychotic Drug Administration
O’Connor, J. A., Hasenkamp, W. M., Horman, B. M., Muly, E. C., & Hemby, S. E. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.044 · Cited by 20
Predictive value of premorbid IQ, negative symptoms, and age for cognitive and social functions in Japanese patients with schizophrenia: A study using the Japanese version of the Brief Assessment of Cognition in Schizophrenia
Akiyama, K., Saitô, S., Saito, A., Ozeki, Y., Watanabe, T., Fujii, K., Honda, G., & Shimoda, K. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.10.070 · Cited by 20
The Course of Neurocognitive Changes in Acute Psychosis: Relation to Symptomatic Improvement
Anda, L. G., Brønnick, K., Johnsen, E., Kroken, R. A., Jørgensen, H. A., & Løberg, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167390 · Cited by 21
Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment
Spellmann, I., Riedel, M. J., Städtler, J., Zill, P., Obermeier, M., Cerovecki, A., Dehning, S., Schennach, R., Epple, M., Opgen-Rhein, M., et al. (2017) · Cognitive Neuropsychiatry · doi:10.1080/13546805.2017.1322502 · Cited by 22
The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia
Selva‐Vera, G., Balanzá‐Martínez, V., Salazar-Fraile, J., Sánchez‐Moreno, J., Martínez‐Arán, A., Correa‐Ghisays, P., Vieta, E., & Tabarés‐Seisdedos, R. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-47 · Cited by 20
The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: A preliminary open-label trial
Suzuki, H., Gen, K., Inoue, Y., Hibino, H., Mikami, A. S., Matsumoto, H., & Mikami, K. (2013) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2013.845218 · Cited by 19
Classifying Antipsychotic Agents
Jindal, R. D., & Keshavan, M. S. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00007 · Cited by 19
Emerging 5-HT receptor antagonists for the treatment of Schizophrenia
Jones, M. T., Strassnig, M., & Harvey, P. D. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1773792 · Cited by 19
Effects of sertindole on cognition in clozapine‐treated schizophrenia patients
Nielsen, R. E., Levander, S. E., Thode, D., & Nielsen, J. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01840.x · Cited by 19
Possible dose–side effect relationship of antipsychotic drugs: relevance to cognitive function in schizophrenia
Sumiyoshi, T. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.6.791 · Cited by 19
Impact of antipsychotic medication on family burden in schizophrenia: Longitudinal results of CATIE trial
PERLICK, D. A., Rosenheck, R. A., Kaczynski, R., Swartz, M. S., Cañive, J. M., & Lieberman, J. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.09.026 · Cited by 19
Self-citation
Differential Effects of Atypical versus Typical Antipsychotic Medication on Earnings of Schizophrenia Patients
Salkever, D. S., Slade, E. P., & Karakus, M. C. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624020-00003 · Cited by 19
Retracted: Effect of blonanserin on cognitive function in antipsychotic‐naïve first‐episode schizophrenia
Tenjin, T., Miyamoto, S., Miyake, N., Ogino, S., Kitajima, R., Ojima, K., Arai, J., 寺本晴樹, Tsukahara, S., Ito, Y., et al. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1276 · Cited by 18
Retracted
The treatment of cognitive dysfunction in schizophrenia
Frangou, S. (2005) · Psychiatry · doi:10.1383/psyt.2005.4.11.46 · Cited by 18
Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS)
Salgado, J. V., Carvalhaes, C. F. R., Pires, A. D. M., das Neves, M. D. C. L., Cruz, B. F., Cardoso, C. S., Lauar, H., Teixeira, A. L., & Keefe, R. S. E. (2007) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642008dn10300007 · Cited by 18
Self-citation
Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: A naturalistic 6-month follow-up study
Wittorf, A., Sickinger, S., Wiedemann, G., & Klingberg, S. (2008) · Archives of Clinical Neuropsychology · doi:10.1016/j.acn.2007.12.005 · Cited by 18
Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms
Manuel Gurpegui, A., Álvarez, E., Bousoño, M., Ciudad, A., Gómez, J. C., & Olivares, J. M. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.04.003 · Cited by 17
Frequency of Attention Deficit in First-Episode Schizophrenia Compared to ADHD
Egeland, J. (2010) · Applied Neuropsychology · doi:10.1080/09084280903297859 · Cited by 17
Patient satisfaction with psychotropic drugs: sensitivity to change and relationship to clinical status, quality-of-life, compliance and effectiveness of treatment. Results from a nation-wide 6-month prospective study
Gasquet, I., Tcherny‐Lessenot, S., Lépine, J., & Falissard, B. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2005.09.014 · Cited by 18
Pharmacological treatment of neurobehavioural sequelae of traumatic brain injury
Lombardi, F. (2008) · European Journal of Anaesthesiology · doi:10.1017/s0265021507003316 · Cited by 17
Posttraumatic brain injury psychosis successfully treated with olanzapine
Viana, B. D. M., Prais, H. A. C., Nicolato, R., & Caramelli, P. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.08.026 · Cited by 16
Executive attention deficits in schizophrenia: Putative mandatory and differential cognitive pathology domains in medicated schizophrenia patients
Meiron, O., Hermesh, H., Katz, N., & Weizman, A. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.09.057 · Cited by 16
Dementia in schizophrenia
Radhakrishnan, R., Butler, R. N., & Head, L. (2012) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.110.008268 · Cited by 15
Fractionation of Verbal Memory Impairment in Schizophrenia and Schizophreniform Psychosis
Wood, S. J., Tarnawski, A. U., Proffitt, T., Brewer, W. J., Savage, G. R., Anderson, V. A., McGorry, P. D., Wood, S. J., Tarnawski, A. U., Proffitt, T., et al. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670701517926 · Cited by 15
Effects of haloperidol on cognitive function and behavioural flexibility in the IntelliCage social home cage environment
Marwari, S., & Dawe, G. S. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111976 · Cited by 15
Olanzapine: a 5-year perspective
Littrell, K. H., Petty, R. G., & Wolf, N. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.6.811 · Cited by 15
Treatment of the first episode of schizophrenia: An update on pharmacologic and psychological interventions
Crespo‐Facorro, B., Pérez‐Iglesias, R., González‐Blanch, C., & Mata, I. F. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0034-1 · Cited by 14
Can genetics inform the management of cognitive deficits in schizophrenia?
Vyas, N. S., Shamsi, S. A. R., Malhotra, A. K., Aitchison, K. J., & Kumari, V. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111434623 · Cited by 14
Psychometric Properties of the Loewenstein Occupational Therapy Cognitive Assessment–Second Edition in Taiwanese Persons With Schizophrenia
Su, C., Chen, W., Tsai, P.-C., Tsai, C.-Y., & Su, W. (2007) · American Journal of Occupational Therapy · doi:10.5014/ajot.61.1.108 · Cited by 14
Therapie kognitiver Defizite durch AChE-Hemmer bei Patienten mit Schizophrenie
Voß, B., Thienel, R., Leucht, S., & Kircher, T. T. J. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2358-1 · Cited by 14
Neurocognitive Effects of Ziprasidone and Related Factors in Patients With Chronic Schizophrenia Undergoing Usual Care
Gibel, A., & Ritsner, M. S. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181572781 · Cited by 14

Authors: Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., Tollefson, G. D., Sanger, T. M., Lieberman, J. A., & HGDH Research Group
Affiliations: Duke University (US)
ORCID: Keefe, Richard S.E.
Seidman, Larry J.
Christensen, Bruce K.
Sitskoorn, Margriet M.
Yurgelun-Todd, Deborah A.
Gur, Ruben C.
Tohen, Mauricio
Sanger, Todd M.
Lieberman, Jeffrey A.
Venue: American Journal of Psychiatry
Publisher: American Psychiatric Association Publishing
Published: 2004-06-01
Volume: 161
Issue: 6
Pages: 985-995
ISSN: 0002-953X (ISSN-L)
1535-7228
DOI: 10.1176/appi.ajp.161.6.985
OpenAlex: W2145453003
Cited by: 314
References: 47
Citations by year: 2026: 1 · 2025: 2 · 2024: 4 · 2023: 12 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 6 · 2017: 7 · 2016: 10 · 2015: 12 · 2014: 9 · 2013: 14 · 2012: 12
FWCI: 24.47
Type: journal article
Language: en
Open access: closed
Locations: American Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords: olanzapine, haloperidol, first-episode psychosis, neurocognitive function, atypical antipsychotics, typical antipsychotics, schizophrenia, schizoaffective disorder, verbal fluency, working memory, verbal memory, sustained attention, anticholinergic effects, extrapyramidal symptoms, IQ, disease duration
MeSH terms: Olanzapine, Adolescent, Adult, Basal Ganglia Diseases, Benzodiazepines, Cognition Disorders, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Haloperidol, Humans, Male, Neuropsychological Tests, Psychotic Disorders, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome, Principal Component Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks